JPWO2022228494A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022228494A5 JPWO2022228494A5 JP2023566659A JP2023566659A JPWO2022228494A5 JP WO2022228494 A5 JPWO2022228494 A5 JP WO2022228494A5 JP 2023566659 A JP2023566659 A JP 2023566659A JP 2023566659 A JP2023566659 A JP 2023566659A JP WO2022228494 A5 JPWO2022228494 A5 JP WO2022228494A5
- Authority
- JP
- Japan
- Prior art keywords
- atoms
- optionally substituted
- linear
- heteroalkyl containing
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004429 atom Chemical group 0.000 claims 41
- 125000004404 heteroalkyl group Chemical group 0.000 claims 26
- 239000000203 mixture Substances 0.000 claims 22
- 229940002612 prodrug Drugs 0.000 claims 22
- 239000000651 prodrug Substances 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 22
- 239000012453 solvate Substances 0.000 claims 22
- 125000003545 alkoxy group Chemical group 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 15
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 108010082974 polysarcosine Proteins 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- -1 cyano, nitro, amino Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 229910052805 deuterium Inorganic materials 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 229960003767 alanine Drugs 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 229960002173 citrulline Drugs 0.000 claims 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical class OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 229960003646 lysine Drugs 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000005649 substituted arylene group Chemical group 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 claims 1
- HXUVTXPOZRFMOY-NSHDSACASA-N 2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]acetic acid Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 HXUVTXPOZRFMOY-NSHDSACASA-N 0.000 claims 1
- VVMAJDPAVPIJGJ-JZGIKJSDSA-N 2-aminoacetic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound NCC(O)=O.NCC(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 VVMAJDPAVPIJGJ-JZGIKJSDSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229960003121 arginine Drugs 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960005261 aspartic acid Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 235000013477 citrulline Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960002989 glutamic acid Drugs 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 229960002743 glutamine Drugs 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 229960002885 histidine Drugs 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960003136 leucine Drugs 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 229960004452 methionine Drugs 0.000 claims 1
- GLZWNFNQMJAZGY-UHFFFAOYSA-N octaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCO GLZWNFNQMJAZGY-UHFFFAOYSA-N 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960005190 phenylalanine Drugs 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229960002429 proline Drugs 0.000 claims 1
- 229960001153 serine Drugs 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 125000005156 substituted alkylene group Chemical group 0.000 claims 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 229960002898 threonine Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 229960004799 tryptophan Drugs 0.000 claims 1
- 229960004441 tyrosine Drugs 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 229960004295 valine Drugs 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110475315 | 2021-04-29 | ||
| CN202110475315.1 | 2021-04-29 | ||
| PCT/CN2022/089725 WO2022228494A1 (zh) | 2021-04-29 | 2022-04-28 | 抗体偶联药物的制备方法及应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024522388A JP2024522388A (ja) | 2024-06-19 |
| JP2024522388A5 JP2024522388A5 (https=) | 2025-03-31 |
| JPWO2022228494A5 true JPWO2022228494A5 (https=) | 2025-03-31 |
Family
ID=83846703
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566660A Pending JP2024522389A (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
| JP2023566547A Pending JP2024522312A (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
| JP2023566659A Pending JP2024522388A (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566660A Pending JP2024522389A (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
| JP2023566547A Pending JP2024522312A (ja) | 2021-04-29 | 2022-04-28 | 抗体薬物複合体の調製方法および使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20240238440A1 (https=) |
| EP (3) | EP4331612A1 (https=) |
| JP (3) | JP2024522389A (https=) |
| KR (2) | KR20240006029A (https=) |
| CN (3) | CN117241834A (https=) |
| AU (1) | AU2022263700A1 (https=) |
| CA (3) | CA3173902A1 (https=) |
| IL (1) | IL308025A (https=) |
| TW (3) | TW202308700A (https=) |
| WO (3) | WO2022228494A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117241834A (zh) * | 2021-04-29 | 2023-12-15 | 上海汇连生物医药有限公司 | 抗体偶联药物的制备方法及应用 |
| IL319963A (en) | 2022-10-19 | 2025-05-01 | Multitude Therapeutics Inc | Antibodies, antibody-drug conjugates, compositions and uses thereof |
| CN120417935A (zh) * | 2022-10-25 | 2025-08-01 | 默沙东有限责任公司 | 依喜替康衍生的adc接头-载荷及其药物组合物和用途 |
| CN120882431A (zh) * | 2023-01-11 | 2025-10-31 | 金麦安博股份有限公司 | 接头、药物接头及其缀合物和使用它们的方法 |
| CN118684724A (zh) * | 2023-03-22 | 2024-09-24 | 映恩生物制药（苏州）有限公司 | 连接子及其在配体药物偶联物中的应用 |
| TW202438069A (zh) * | 2023-03-30 | 2024-10-01 | 大陸商上海齊魯製藥研究中心有限公司 | 依喜替康衍生物及其抗體藥物偶聯物 |
| WO2024212922A1 (zh) * | 2023-04-11 | 2024-10-17 | 映恩生物制药（苏州）有限公司 | 喜树碱类化合物及其偶联物、其制备方法和用途 |
| CN118852442A (zh) | 2023-04-26 | 2024-10-29 | 上海麦科思生物医药有限公司 | 抗ptk7抗体及其用途 |
| CN119300868B (zh) * | 2023-05-11 | 2026-03-13 | 映恩生物科技(上海)有限公司 | 喜树碱类化合物及其偶联物、其制备方法和用途 |
| EP4713020A2 (en) * | 2023-05-19 | 2026-03-25 | Solve Therapeutics, Inc. | Drug-linkers and drug conjugates |
| CN121772941A (zh) * | 2023-06-07 | 2026-03-31 | 维申医药(南通)有限公司 | 一种抗体药物偶联物，及其药物组合物、制备和用途 |
| WO2025005240A1 (ja) * | 2023-06-30 | 2025-01-02 | 第一三共株式会社 | 活性炭材料を使用する精製工程を含む抗体－薬物コンジュゲートの製造方法 |
| AU2024288808A1 (en) | 2023-07-07 | 2026-01-22 | Shanghai Escugen Biotechnology Co., Ltd. | Linker-drug molecule and antibody drug conjugate, preparation method therefor and use thereof |
| IL326233A (en) * | 2023-08-04 | 2026-03-01 | Shanghai Huao Co Ltd | Multidrug Linker and Antibody-Drug Conjugation |
| CN120641100A (zh) * | 2023-09-22 | 2025-09-12 | 台湾浩鼎生技股份有限公司 | 用于抗体耦合的改良型连接符-负载物、医药组合物、及其应用 |
| TW202525860A (zh) * | 2023-10-23 | 2025-07-01 | 大陸商上海齊魯製藥研究中心有限公司 | 喜樹鹼類藥物耦合物及其製備方法和應用 |
| EP4566631A1 (en) * | 2023-12-06 | 2025-06-11 | Heidelberg Pharma Research GmbH | New antibody drug conjugate as well as methods of production and uses thereof |
| WO2025149019A1 (en) * | 2024-01-12 | 2025-07-17 | Shanghai Ruotuo Biosciences Co., Ltd. | Antibody-drug conjugates, pharmaceutical compositions, and therapeutic applications |
| WO2025153092A1 (en) * | 2024-01-18 | 2025-07-24 | Beijing Joinn Biologics Co., Ltd | Antibody-drug conjugate |
| WO2025171055A1 (en) | 2024-02-06 | 2025-08-14 | Kumquat Biosciences Inc. | Heterocyclic conjugates and uses thereof |
| WO2025209545A1 (zh) * | 2024-04-03 | 2025-10-09 | 上海药明合联生物技术有限公司 | 用于抗体药物偶联物的连接子、其用途和由其制备的抗体药物偶联物 |
| WO2025222052A2 (en) * | 2024-04-18 | 2025-10-23 | Solve Therapeutics, Inc. | Conjugates and uses thereof |
| WO2025259928A1 (en) * | 2024-06-13 | 2025-12-18 | Obi Pharma, Inc. | Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof |
| WO2025261478A1 (en) * | 2024-06-21 | 2025-12-26 | Biotheus Inc. | Antibody drug conjugates and applications thereof |
| WO2026039642A1 (en) | 2024-08-16 | 2026-02-19 | Ardeagen Corporation | Anti-mesothelin antibody conjugates and methods of use thereof |
| WO2026037394A1 (zh) * | 2024-08-16 | 2026-02-19 | 石药集团巨石生物制药有限公司 | 一种抗体药物偶联物及其用途 |
| WO2026046186A1 (en) * | 2024-08-27 | 2026-03-05 | Suzhou Bioreinno Biotechnology Limited Company | Linkers, linker conjugates and conjugate compounds thereof |
| WO2026067624A1 (zh) * | 2024-09-27 | 2026-04-02 | 上海森辉医药有限公司 | 一种包含亲水基团的配体-药物偶联物及其在医药上的应用 |
| CN119143876B (zh) * | 2024-10-09 | 2025-09-16 | 武汉海沙百得生物技术有限公司 | 一种抗cd27l的全人源抗体或抗体片段及其应用 |
| WO2026078443A1 (en) | 2024-10-11 | 2026-04-16 | Pheon Therapeutics Ltd. | Antibody drug conjugates that bind cdcp1 and uses thereof |
| CN120484249B (zh) * | 2025-04-29 | 2026-03-10 | 中山大学 | 一种含氟修饰的聚肌氨酸化脂质及其制备方法和应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391745A (en) * | 1992-07-23 | 1995-02-21 | Sloan-Kettering Institute For Cancer Research | Methods of preparation of camptothecin analogs |
| DE60235287D1 (de) * | 2001-11-14 | 2010-03-25 | Univ Rutgers | Löslich gemachte topoisomerase-gifte |
| WO2003074566A2 (en) | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Rs7 antibodies |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| RU2015129800A (ru) * | 2012-12-21 | 2017-01-30 | Биоэллаенс К. В. | Гидрофильные саморазрушающиеся линкеры и их конъюгаты |
| RU2019115089A (ru) | 2013-04-16 | 2019-06-11 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| WO2014177042A1 (zh) * | 2013-04-28 | 2014-11-06 | Qin Gang | 一种新型的连接子及其制备方法和用途 |
| LT3424955T (lt) * | 2013-12-25 | 2025-06-25 | Daiichi Sankyo Company, Limited | Anti-trop2 antikūno ir vaisto konjugato gamybos būdas |
| AU2015252518B2 (en) * | 2014-04-29 | 2019-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | New stable antibody-drug conjugate, preparation method therefor, and use thereof |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| EP4180455A1 (en) | 2015-06-29 | 2023-05-17 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| US10675357B2 (en) | 2015-09-09 | 2020-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to nectin-4 and uses thereof |
| CN108066772B (zh) * | 2016-11-14 | 2021-07-13 | 中国科学院上海药物研究所 | 靶向tacstd2的抗体与药物偶联体(adc)分子 |
| TW202532102A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| JP7381478B2 (ja) * | 2017-10-23 | 2023-11-15 | マブリンク ビオシオンス | 単一分子量ポリサルコシンを含むリガンド－薬物－複合体 |
| KR20220010527A (ko) * | 2019-05-20 | 2022-01-25 | 노파르티스 아게 | 친수성 기를 포함하는 링커를 갖는 항체 약물 콘쥬게이트 |
| JP7167163B2 (ja) | 2019-05-20 | 2022-11-08 | 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 | 抗体－薬物コンジュゲートの中間体のワンポット合成法による製造プロセス |
| CN117241834A (zh) * | 2021-04-29 | 2023-12-15 | 上海汇连生物医药有限公司 | 抗体偶联药物的制备方法及应用 |
-
2022
- 2022-04-28 CN CN202280030774.1A patent/CN117241834A/zh active Pending
- 2022-04-28 TW TW111116236A patent/TW202308700A/zh unknown
- 2022-04-28 EP EP22794964.1A patent/EP4331612A1/en active Pending
- 2022-04-28 WO PCT/CN2022/089725 patent/WO2022228494A1/zh not_active Ceased
- 2022-04-28 US US18/557,448 patent/US20240238440A1/en active Pending
- 2022-04-28 CA CA3173902A patent/CA3173902A1/en active Pending
- 2022-04-28 CA CA3173758A patent/CA3173758A1/en active Pending
- 2022-04-28 JP JP2023566660A patent/JP2024522389A/ja active Pending
- 2022-04-28 KR KR1020237041142A patent/KR20240006029A/ko active Pending
- 2022-04-28 WO PCT/CN2022/089726 patent/WO2022228495A1/zh not_active Ceased
- 2022-04-28 TW TW111116237A patent/TW202308701A/zh unknown
- 2022-04-28 TW TW111116233A patent/TW202309045A/zh unknown
- 2022-04-28 US US18/557,454 patent/US20240245799A1/en active Pending
- 2022-04-28 WO PCT/CN2022/089724 patent/WO2022228493A1/zh not_active Ceased
- 2022-04-28 US US18/557,445 patent/US20240245795A1/en active Pending
- 2022-04-28 EP EP22794963.3A patent/EP4331611A1/en active Pending
- 2022-04-28 CA CA3173511A patent/CA3173511A1/en active Pending
- 2022-04-28 AU AU2022263700A patent/AU2022263700A1/en active Pending
- 2022-04-28 KR KR1020237041141A patent/KR20240006028A/ko active Pending
- 2022-04-28 CN CN202280030770.3A patent/CN117241833A/zh active Pending
- 2022-04-28 JP JP2023566547A patent/JP2024522312A/ja active Pending
- 2022-04-28 JP JP2023566659A patent/JP2024522388A/ja active Pending
- 2022-04-28 IL IL308025A patent/IL308025A/en unknown
- 2022-04-28 CN CN202280030781.1A patent/CN117337195A/zh active Pending
- 2022-04-28 EP EP22794965.8A patent/EP4331613A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022228494A5 (https=) | ||
| JPWO2022228495A5 (https=) | ||
| JP2022511351A5 (https=) | ||
| JPWO2022228493A5 (https=) | ||
| Elgersma et al. | Design, synthesis, and evaluation of linker-duocarmycin payloads: toward selection of HER2-targeting antibody–drug conjugate SYD985 | |
| HRP20250345T1 (hr) | Konjugati antitijelo - lijek derivata cikličnih dinukleotida | |
| JP2024522388A (ja) | 抗体薬物複合体の調製方法および使用 | |
| JP2012516896A5 (https=) | ||
| JP2017525755A5 (https=) | ||
| JP2012522512A5 (https=) | ||
| JP2017514905A5 (https=) | ||
| JP2012522513A5 (https=) | ||
| KR20190104995A (ko) | 벤조다이아제핀 유도체의 선택적인 설폰화 | |
| RU2017101681A (ru) | Конъюгаты анти-cd22 антитело - лекарственное средство и способы их применения | |
| JPWO2020236825A5 (https=) | ||
| WO2024041542A1 (en) | A method for programmatically managing antibody disulfide bonds site-specific modification | |
| JP2016510730A5 (https=) | ||
| JP2019507126A (ja) | ツブリシン類似体およびこれらの調製のための方法 | |
| RU2007101074A (ru) | Фармацевтическая противораковая композиция пролина или его производных и противоопухолевого антитела | |
| JPWO2020106780A5 (https=) | ||
| RU2025110275A (ru) | Лекарственное средство на основе ауристатина с высокостабильным гидрофильным линкерным элементом и его конъюгат | |
| JPWO2022262789A5 (https=) | ||
| RU2023112017A (ru) | Дейтерированное производное камптотецина и включающий его конъюгат антитело-лекарственное средство | |
| WO2024041541A1 (en) | A novel thiol reductant, method and use thereof | |
| JPWO2020065408A5 (https=) |